Fox Chase Cancer Center News

PHILADELPHIA (March 16, 2021) — The drug ibrutinib, also known by the brand name Imbruvica, can be an effective tool to slow or stop tumor growth in lymphoma, a type of B-cell neoplasia. But for patients who become resistant to the medication, there are a limited number of other options. Now, new research by Fox Chase Cancer Center physician-scientists opens the door for alternative treatments

PHILADELPHIA (March 12, 2021)—Researchers at Fox Chase Cancer Center recently conducted a study that showed the immunotherapy drug pembrolizumab, also known by the brand name Keytruda, has limited treatment efficacy when used alone in the treatment of high-grade neuroendocrine neoplasms (G3 NENs).

PHILADELPHIA (March 12, 2021)—Stephanie Greco, MD, assistant professor in the Department of Surgical Oncology at Fox Chase Cancer Center, was recently named a new councilor for the Association for Academic Surgery (AAS).

PHILADELPHIA (March 11, 2021)—Scientists have learned that the socioeconomic circumstances of a neighborhood, including housing and employment, are related to cancer risk and outcomes. But to date, only a handful of measures, such as poverty, have been analyzed.

PHILADELPHIA (March 11, 2021)—According to research by Daniel M. Geynisman, MD, associate professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium, some patients with muscle-invasive urothelial carcinoma, a form of bladder cancer, may not need to have their bladder removed.

PHILADELPHIA (March 11, 2021) – A nursing team at Fox Chase Cancer Center has been honored as a recipient of the 2021 I AM Patient Safety award from the Patient Safety Authority. The team was awarded the Executive Director’s Choice award, making it one of 11 healthcare facilities in Pennsylvania to be recognized for their advancements, outcomes, and commitment to patient safet

PHILADELPHIA (March 10, 2021)—Jennifer Barsky Reese, PhD, associate professor for the Cancer Prevention and Control Program at Fox Chase Cancer Center, was recently recognized with the New Investigator Award from the American Psychosocial Oncology Society (APOS).

PHILADELPHIA (March 10, 2021)— Researchers from Fox Chase Cancer Center have demonstrated that fitness trackers such as Fitbit are feasible tools for assessing performance status—the ability to perform activities of daily living—in colorectal cancer patients. The finding is important because performance status is used to determine whether cancer patients may tolerate more or less aggressive forms of treatment and how they are holding up during treatment.